View details of this raise on Seedstage

New York, NY

Developing a precision oncology platform to improve cancer treatment decisions.

• Precision Oncology Platform: Stratifind’s platform uses DNA and RNA data to guide cancer treatment decisions.
• RainDanceEQ Test: The test integrates multi-omic data to provide actionable insights into tumor biology.
• Seamless Clinical Integration: Designed to fit into existing oncology workflows, enhancing treatment decision-making.
• Asset-Light Model: Focuses on data interpretation and reporting, leveraging partner labs for sequencing.
• Scalable Growth Strategy: Aims to expand access to precision oncology tools through established reimbursement pathways.

Stratifind is developing a precision oncology platform aimed at improving cancer treatment decisions through advanced diagnostics. The company’s flagship test, RainDanceEQ, utilizes DNA and RNA data to provide actionable insights into tumor biology, helping oncologists select the most effective therapies from the outset. This approach seeks to reduce the trial-and-error nature of current cancer treatments by offering a more comprehensive understanding of each patient’s disease.

The platform is designed to integrate seamlessly into existing clinical workflows, providing oncologists with clear, evidence-based treatment guidance. Stratifind’s asset-light model focuses on data interpretation and reporting, leveraging partner laboratories for sequencing. This strategy aims to support scalable growth and broader access to precision oncology tools. By aligning with established reimbursement pathways, Stratifind intends to facilitate the adoption of its platform in everyday oncology care, ultimately enhancing patient outcomes and reducing healthcare costs.

Company Info

Stratifind provides a precision oncology platform that uses DNA and RNA data to guide cancer treatment decisions.

Stratifind is a precision oncology platform focused on providing actionable insights for cancer treatment through its flagship test, RainDanceEQ™. This test utilizes DNA and RNA data to guide therapy decisions, aiming to improve clinical outcomes by eliminating the trial-and-error approach in oncology. The platform integrates next-generation sequencing with proprietary algorithms to deliver a comprehensive view of tumor biology, helping oncologists make informed treatment choices from the outset.

The company operates an asset-light model, partnering with CLIA-certified laboratories for sequencing while focusing on data interpretation and reporting. Stratifind’s approach is designed to fit seamlessly into existing clinical workflows, providing oncologists with clear, ranked treatment strategies. By leveraging established reimbursement pathways, the platform aims to support broader access to precision oncology, ultimately enhancing the decision-making process for both physicians and patients.